Biocon And Mylan Get CRL From FDA For Lantus Rival
Executive Summary
Biocon has run into fresh trouble with the US Food and Drug Administration after receiving a complete response letter on its application for insulin glargine, a proposed rival to Sanofi’s top-selling Lantus biologic.